Please assess the completion status of the following clinical trial:

Trial Title: Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal or less than 65 years old and equal to or greater than 18 years old.~* Patients with the diagnosis of MDS or AML with fewer than 5% myeloblasts in the bone marrow and no leukemic myeloblasts in the peripheral blood on morphologic analysis performed within 30 days of start of the conditioning regimen enrollment.~* For patients receiving treatment of their MDS or AML prior to transplantation: a)Interval between the start of the most recent cycle of conventional cytotoxic chemotherapy and enrollment must be at least 30 days; b)Interval between completing treatment with a hypomethylating agent or other non-cytotoxic chemotherapy and enrollment must be at least 10 days.~* Patients must have a related or unrelated bone marrow or peripheral blood donor who is human leukocyte antigen (HLA)-matched at 7 or 8 of 8 HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing.~* HCT-Specific Comorbidity Index Score (HCT-CI) less than or equal to 4.~* Organ function: a) Cardiac function: Ejection fraction greater than or equal to 40%; b) Hepatic function: total bilirubin less than or equal to 2 times the upper limit of normal and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 3 times the upper limit of normal.; c)Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) greater than or equal to 40% and forced expiratory volume in one second (FEV1) greater than or equal to 50% (corrected for hemoglobin).~* Creatinine clearance greater than or equal to 50mL/min based on the Cockcroft-Gault formula.~* Signed informed consent.~Exclusion Criteria:~* Prior allograft or prior autograft.~* Symptomatic coronary artery disease.~* Leukemia involvement in the central nervous system (CNS) within 4 weeks of enrollment for patients with a history of prior CNS leukemia involvement (i.e., leukemic blasts previously detected in the cerebral spinal fluid).~* Karnofsky Performance Score less than 70.~* Patients receiving supplemental oxygen.~* Planned use of donor lymphocyte infusion (DLI) therapy.~* Patients with uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms).~* Patients seropositive for the human immunodeficiency virus (HIV).~* Patients with prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent greater than 5 years previously. Cancer treated with curative intent less than 5 years previously will not be allowed unless approved by the Protocol Officer or one of the Protocol Chairs.~* Females who are pregnant or breastfeeding.~* Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Reduced Intensity Conditioning (RIC) (Type: EXPERIMENTAL): One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
- Myeloablative Conditioning Regimen (MAC) (Type: ACTIVE_COMPARATOR): One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).